The New York Genome Center (NYGC) is an independent, nonprofit academic research institution that serves as a multi-institutional hub for genomic research. Leveraging our strengths in whole-genome sequencing and genomic analysis, our mission is the advancement of genomic science and its application to drive novel biomedical discoveries. NYGC’s areas of focus include the development of computational and experimental genomic methods and disease-focused research to better understand the genetic basis of cancer, neurodegenerative disease, and neuropsychiatric disease. In 2020, the NYGC also has directed its expertise to COVID-19 research.
We are committed to prioritizing diversity, equity, and inclusion, which is fundamental to promoting greater collaboration, innovation, and discovery. Learn more about NYGC’s Commitment to Diversity, Equity, and Inclusion.
2021 NYGC ALS Consortium Meeting: Celebrating Achievements, Ongoing Collaborations to Advance ALS Research
VIDEO: Michael Zody, PhD, Discusses Collaborative SARS-CoV-2 Viral Surveillance Initiatives at the NYGC
Sanjana Lab of NYGC/NYU Extends RNA-Targeting CRISPR-Cas13 Genomics Tools to Model Organisms and Viruses Including SARS-CoV-2
Tom Maniatis, PhD, NYGC Evnin Family Scientific Director & CEO, Named to City & State’s First “Life Sciences Power 50” List
NYGC board members, scientists from NYGC member institutions, and NYGC collaborative partners and supporters are also among the honorees recognized as forward-thinking leaders driving the life sciences sector’s growth in New York.
Sanjana Lab of NYGC/NYU Boosts Gene Knockdown in Human Cells With CRISPR-Cas13 Using Chemically-Modified Guide RNAs
01 / 02
Nature Biotechnology. 2021 Sept. 9.
Communications Biology. 2021 Sept. 1.